Gyre Therapeutics, Inc. reported $119M of revenue over the trailing twelve months, +14% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $119M (to Q2 2026). Net income: −$28M, trailing twelve months to Q2 2026. Free cash flow: −$6.1M, trailing twelve months to Q2 2026. Operating margin: −17%, trailing twelve months to Q2 2026.

GYREGyre Therapeutics, Inc.

Healthcare

$6.76-7.0% 1Y

$6.76

$5.5652 weeks$8.87

GYRE as reported

Gyre Therapeutics, Inc. reported $119M of revenue over the trailing twelve months, +14% on the year before. 10 reported series are charted on this page, each one as filed.

$119M

Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before

Net income: −$28M
Net income · −559% year on year · trailing twelve months to Q2 2026
Free cash flow: −$6.1M
Free cash flow · −38% year on year · trailing twelve months to Q2 2026
Operating margin: −17%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GYRE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$119M	+14%	Q2 2026
Net income	−$28M	−559%	Q2 2026
EPS	−$0.21	+950%	Q2 2026
Gross margin	94%	n/a	Q2 2026
Operating margin	−17%	n/a	Q2 2026
Net margin	−29%	n/a	Q2 2026
ROE	−5.3%	n/a	Q2 2026
ROA	−3.8%	n/a	Q2 2026
ROIC	−65%	n/a	Q4 2014 · 46 quarters behind
Free cash flow	−$6.1M	−38%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.